Clinical trial · Interventional
A Cohort Study of Beta-Glucan or Beta-Glucan Compound in Metastatic Cancers
A Cohort Study to Evaluate the Efficacy of Beta-Glucan or Beta-Glucan Compound (Combined With Glutamine and Immunoglobulin) Supplement in Patients With Metastatic Cancers Undergoing Chemotherapy
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Immunity of cancer patients is an important issue. According to cancer immunity, it can be divided into three phases: clearance phase, equilibrium phase, and escape phase (cancer cells can avoid the recognition of immune cells). Βeta-glucans is extracted from yeast, it can increase immune function and drive of hematopoietic stem cells in animals and clinical trials. Glutamine can increase the repair of oral and intestinal mucosa of patients receiving chemical and radiation therapy and can increase the lymphocytes of patients. Colostrum contains IgA, IgG, IgM, etc., known to protect the baby Cancer patients who are infected with intestinal bacteria and undergo systemic chemotherapy are less immune than normal adults. Investigators will compare β-glucan, glutamine, and colostrum immunoglobulin powder with β-glucan and control group, each group has 30 people, and observe the side effects and blood of patients under standard chemotherapy. The performance of the immune system, such as helpers and cytotoxic T cells and NK cells, and to observe the differences in treatment interruption or delay rates and treatment rates.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Chemotherapy | — | UNRESOLVED | — |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Beta-Glucan | Dietary Supplement | — | UNRESOLVED |
| Corn starch | Dietary Supplement | — | UNRESOLVED |
| Glutamine | Dietary Supplement | — | UNRESOLVED |
| Immunoglobuin | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Solid beverage powder
- description
- Whey portein solid beverage powder use 1 pack for every 10 kg of body weight. A total of 6 pack under 60 kg a day, an extra 1pack for each additional 10 kg over 60 kg.Use from the 7th day of the 2nd course of treatment for 5 months.
- interventionNames
- Dietary Supplement: Beta-Glucan
- Dietary Supplement: Glutamine
- Dietary Supplement: Immunoglobuin
- type
- EXPERIMENTAL
- label
- Capsule
- description
- Capsules use 1 cap for every 10 kg of body weight.A total of 6 cap under 60 kg a day, an extra 1cap for each additional 10 kg over 60 kg. Use from the 7th day of the 2nd course of treatment for 5 months.
- interventionNames
- Dietary Supplement: Beta-Glucan
- type
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with metastatic cancer receiving systemic chemotherapy * ECOG=0,1 * Age ≥20 years * Chemotherapy drugs include platinum drugs (cisplatin, carboplatin, oxaliplatin), irinotecan / topotecan, paclitaxel (docetaxel), fluorouracil (5-FU), and alkylating drugs (such as cyclophosphamide) Exclusion Criteria: * Early cancer patients. * Patients receiving systemic chemotherapy or large-area radiation therapy 6 months before chemotherapy. * The patient had a history of allergies to β-glucan or glutamine. * Patients with liver dysfunction not associated with cancer. (GOT\> 2 × ULN; GPT\> 2 × ULN) * Patients with abnormal renal function (creatinine over 2 mg / dl) * Age \<20 years
References
Publications (0)
Data not yet available